Preparation and Clinical Administration of the Cryopreserved Red Blood Cells and Platelets

Высочин, И. В.; Кобзева, Е. Н.; Макаров, М. С.; Глухов, А. С.; Тюрин, Ю А; Клюев, А. Е.; Хватов, В. В.

doi:10.18786/2072-0505-2014-30-70-75

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the studies published so far, no severe reactions were reported following administration of frozen platelets and this was confirmed by our observation. Furthermore, no negative effect of increased coagulation activity of the cryopreserved platelets was observed [36,48].…”

Section: Cryopreservation Biotechnology In Biomedical and Biological mentioning

confidence: 96%

Cryopreservation of Platelets: Advances and Current Practice

Bohoněk¹

2018

Cryopreservation Biotechnology in Biomedical and Biological Sciences

View full text Add to dashboard Cite

Conventional fresh platelets stored at 20-24°C have a short shelf life, at most 7 days. Their main disadvantage is logistics as it is more difficult. This limitation is especially problematic for emergency and intensive care departments for managing massive bleeding. The early and aggressive use of blood products for massive hemorrhage may correct coagulopathy, control bleeding, and improve outcomes. The timely availability of platelets at the shortest time after the injury is often problematic. Many hospitals cannot afford to have platelets permanently in stock because of its short shelf life. Cryopreservation and storage of frozen platelets may significantly prolong their shelf life. Thus, frozen platelets provide long-term accessibility in situations where fresh products are not available. The most widely used method for the platelets cryopreservation is freezing at 5-6% DMSO at −80°C. The production of cryopreserved platelets is not technologically demanding, they can be easily thawed and reconstituted. Frozen platelets are an alternative blood product for urgent orders in connection with heavy bleeding. They are cost-effective functional platelets product for the management of bleeding and should be considered for wider use in clinical practice, such as autologous platelets, rare or HLA/HPA compatible platelets and platelets for non-transfusion use.

show abstract

Section: Cryopreservation Biotechnology In Biomedical and Biological mentioning

confidence: 96%

Cryopreservation of Platelets: Advances and Current Practice

Bohoněk¹

2018

Cryopreservation Biotechnology in Biomedical and Biological Sciences

View full text Add to dashboard Cite

show abstract

“…Согласно литературным данным [7][8][9][10] По данным литературы, среднее значение функциональной активности тромбоцитов (ФАТ) в крови пациента при трансфузиях ТКК к , заготовленных этим методом, была такая же, как при переливании ТКК 1-2-х суток хранения, и в 1,9-2,2 раза выше, чем при переливании ТКК 3-4-х суток хранения при 20-24 °С [9,11].…”

Section: резюме _____________________________________________________...unclassified

“…Клинические исследования тромбоцитов, меченных радиофармпрепаратом, показали, что размороженные тромбоциты оказывают гемостатический эффект и рециркулируют в кровяном русле реципиента. Несмотря на достаточный опыт производства и клинического применения ТКК во всем мире, методики криоконсервирования тромбоцитов полностью не удовлетворяют современным требованиям по параметрам: ФАТ в исходном ТКК, до их криоконсервирования; большая потеря тромбоцитов в результате удаления КК; низкая сохранность тромбоцитов после размораживания; посттрансфузионные токсические осложнения, к которым приводит переливание пациенту тромбоцитов без удаления КК; трудозатратность существующих технологий криоконсервирования тромбоцитов [7,16,23].…”

Section: резюме _____________________________________________________...unclassified

Platelet Сryopreservation: Technologies and Control Methods

Дашкевич,

Романчук,

Бухвальд

et al. 2024

Гематология. Трансфузиология. Восточная Европа

View full text Add to dashboard Cite

Трансфузии тромбоцитов как компонента заместительной терапии являются в настоящее время общепринятым методом профилактики и лечения геморрагического синдрома при тромбоцитопении различного генеза. Существующие в настоящее время технологии заготовки тромбоцитных концентратов крови с условиями хранения (постоянное помешивание при температуре 20±2 °С) предусматривают возможности сохранения качества тромбоцитов только в течение пяти суток от момента заготовки, что обуславливает проблему создания резерва ТКК, в частности при сложных фенотипических подборах по HLA- и HPA-системам. Возможным решением данных проблем является внедрение процедуры криоконсервирования тромбоцитов, что позволит создать стратегический запас, а также снизить риск передачи трансфузионно-трансмиссивных инфекций за счет проведения карантинизации компонента. В обзоре литературы рассматриваются вопросы использования различных технологий криоконсервирования тромбоцитов, преимущества и недостатки различных криопротекторов, методы контроля качества тромбоцитов криоконсервированных. Platelet transfusions, as a component of replacement therapy, are currently a generally accepted method for the prevention and treatment of hemorrhagic syndrome in thrombocytopenia of various origins. Current technologies for the preparation of platelet blood concentrates with storage conditions (constant stirring at a temperature of 20±2°C) provide for the possibility of preserving the quality of platelets only for five days from the moment of preparation, which raises the problem of creating a TBC reserve, in particular, with complex phenotypic selections based on HLA and HPA systems. A possible solution to these problems is the introduction of a procedure for cryopreservation of platelets, which will create a strategic reserve and also reduce the risk of transmission of transfusion-borne infections through quarantine of the component. The literature review examines the use of various platelet cryopreservation technologies, the advantages and disadvantages of various cryoprotectors, and methods for quality control of cryopreserved platelets.

show abstract

“…According to the modern data, the safest RBC-containing environment for recipient are thawed washed RBCs [4,5,6,7]. Cryobiology success allowed to consider cryopreservation to be an effective method of long-term blood cell storage [8,9,10,11,12]. There are two technological possibilities to cryopreserve RBCs.…”

Section: Introductionmentioning

confidence: 99%

Prolonged Storage of Thawed Red Blood Cells

Orlyk

Kondratskyi²,

Vynarchyk³

et al. 2022

Proc Shevchenko Sci Soc Med Sci

View full text Add to dashboard Cite

Introduction. In modern transfusion practice, both in peacetime and in military conditions, red blood cells (RBCs) are widely used as the main component of donor blood. Cryopreserved red blood cells are considered the most safe and high-quality RBC-containing environment. However, the storage period of thawed RBCs after cryopreservation is limited to 24 hours, and significantly complicates their use. Therefore, extending the storage period of thawed RBCs is relevant for the blood service. Research objective: study the RBCs morphological state and functional completeness that were cryopreserved at -40ºС and stored for 7 days at a temperature of +2ºС - +4ºС after thawing. Materials and methods. The object of the study were RBCs that were cryopreserved at -40ºС and stored for 7 days at a temperature of +2ºС - +4ºС after thawing. Deglycerolization of the thawed red blood cells, cryopreserved at -40ºС, required three time washing by using reverse cytoagglomeration. Thawed RBCs were re-suspended in lactate-sucrose-phosphate solution. After RBC thawing and storage for 7 days (186 doses) in the suspension the following indicators were studied: free hemoglobin, extracellular potassium, adenosine triphosphoric acid (ATP), 2,3-diphosphoglycerate (2,3-DPG), hematocrit, degree of hemoglobin affinity to oxygen (P50,), viscosity coefficient, osmotic stability, electrophoretic mobility of erythrocytes. as well as the total number of cells lost and recovered. Results. After storage for 7 days of suspension of thawed RBCs at a temperature of +2ºС - +4ºС indicators of free hemoglobin (0,62±0,02 g/l), extracellular potassium (2,7±0,3 mmol/l), hematocrit (0,4±0,02 l/l) were within normal limits. Osmotic resistance (0,46±0,02%), electrophoretic mobility (0,94±0,04 µm·cm·V-1·s-1) of RBCs, suspension viscosity factor (5,5±0,20mPa·С) did not exhibit changes in comparison with normal values. High levels of ATP indicators (3,0±0,2 µmol/gHb) and 2,3-DPG (10,5±1,3 µmol/gHb) were established. Indicator Р50 (24,1±1,3 hPa) corresponded to low hemoglobine affinity for oxygen. After 7-day storage at +2ºС - +4ºС total cell loss was insignificant and amounted to 5,6±0,4%. High percentage of viable thawed RBCs 94,4±0,5% was shown. Conclusions. Deglycerolization of thawed red blood cells, cryopreserved at -40ºС, by reverse cytoagglomeration, as well as use of lactate-sucrose-phosphate solution for washed RBCs resuspending promote prolongation of thawed RBCs storage period up to 7 days at +2ºС - +4ºС in viable condition.

show abstract

Preparation and Clinical Administration of the Cryopreserved Red Blood Cells and Platelets

Cited by 4 publications

References 0 publications

Cryopreservation of Platelets: Advances and Current Practice

Cryopreservation of Platelets: Advances and Current Practice

Platelet Сryopreservation: Technologies and Control Methods

Prolonged Storage of Thawed Red Blood Cells

Contact Info

Product

Resources

About